Matt Miksic

“I wanted to, if we could talk just a little bit about some of the initiatives that you mentioned around BD Excellence and Excellence in Manufacturing.”

“Maybe just, you know, maybe help us understand how you think about the near-term effects before we get to the point of guidelines, NCD, et cetera. What challenges, if there are challenges in the clinical referral community, do you think that this solves or helps kind of move along?”

“But one question just following up on the market, you know, there was some kind of unusual trajectory during last year in terms of the market. Based on your best guess and what you saw, I guess, during and exiting Q4 on the calendar basis, do you think that's, you know, improving now?”

“Thanks so much for taking the questions, and congrats again on a really strong finish to this year and strong guide. So, one question on some of the leverage that you've been delivering.”

“Just maybe looking at some of the strength in knees and the core geographically, and maybe talk a little bit about pockets of strength. where you're seeing success, you know, the sort of cadence of the iodine-coated launch in Japan, sort of that geographic breakdown in any color you could provide would be great.”